Nexreet Ceutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 04-01-2025
- Paid Up Capital ₹ 1.00 Cr
as on 04-01-2025
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.80 Cr
as on 04-01-2025
- Satisfied Charges ₹ 3.30 Cr
as on 04-01-2025
About Nexreet Ceutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹9.80 Cr. The company has closed loans amounting to ₹3.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vikrant Suryawanshi, Ratnakar Tukaram, and Yogesh Nemade serve as directors at the Company.
- CIN/LLPIN
U24239MH2021PTC370287
- Company No.
370287
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Oct 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nexreet Ceutics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikrant Suryawanshi  | Director | 26-Oct-2021 | Current |
| Ratnakar Tukaram | Director | 26-Oct-2021 | Current |
| Yogesh Nemade | Director | 26-Oct-2021 | Current |
Financial Performance of Nexreet Ceutics.
Enhance accessibility to Nexreet Ceutics's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nexreet Ceutics?
Unlock access to Nexreet Ceutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Shreesurya Pharma Private LimitedActive 8 years 10 monthsVikrant Suryawanshi and Ratnakar Tukaram are mutual person
Shree Surya Surgi Pharma Private LimitedActive 14 years 1 monthVikrant Suryawanshi and Ratnakar Tukaram are mutual person
Charges (Loans)
₹9.80 Cr
₹3.30 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 9.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Nov 2024 | State Bank Of India | ₹9.80 Cr | Open |
| 08 Aug 2023 | Others | ₹1.50 M | Satisfied |
| 08 Aug 2023 | Others | ₹3.15 Cr | Satisfied |
How Many Employees Work at Nexreet Ceutics?
Nexreet Ceutics has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexreet Ceutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexreet Ceutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.